Showing results (521-530 of 744) with videos related to

Sort By:
Pageof 75
Journal of Global Oncology|November 27, 2019
Breast Cancer Care Quality in South Africa's Public Health System: An Evaluation Using American Society of Clinical Oncology/National Quality Forum MeasuresDaniel S O'Neil, Wenlong Carl Chen, Oluwatosin Ayeni, et al.
JAMA Network Open|December 9, 2020
Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial CancerClaire J Tobias, Ling Chen, Alexander Melamed, et al.
Cancer Chemotherapy and Pharmacology|June 29, 2018
A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostatCody J Peer, Oliver M Hall, Tristan M Sissung, et al.
Molecular and Cellular Biochemistry|November 13, 2008
The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variantOrsolya Polgar, John F Deeken, Lilangi S Ediriwickrema, et al.
Oncogene|January 16, 2002
Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor familyPhilippe C Bishop, Timothy Myers, Robert Robey, et al.
Cancer Research|April 5, 2012
Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporterAgnes Basseville, Akina Tamaki, Caterina Ierano, et al.
Cell Cycle (Georgetown, Tex.)|April 23, 2005
Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatinApril R Robbins, Sandra A Jablonski, Tim J Yen, et al.
Cancer Research|November 5, 2002
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumorsJerry Jaboin, Jason Wild, Habib Hamidi, et al.
Molecular Cancer Therapeutics|December 17, 2002
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicityMikhail V Blagosklonny, Robert Robey, Dan L Sackett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2012
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growthWilfred D Stein, Julia Wilkerson, Sindy T Kim, et al.
Pageof 75